Market capitalization | $275.09m |
Enterprise Value | $221.92m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 40.28 |
P/S ratio (TTM) P/S ratio | 49.93 |
P/B ratio (TTM) P/B ratio | 2.35 |
Revenue growth (TTM) Revenue growth | 35.22% |
Revenue (TTM) Revenue | $5.51m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Nyxoah SA forecast:
9 Analysts have issued a Nyxoah SA forecast:
Sep '24 |
+/-
%
|
||
Revenue | 5.51 5.51 |
35%
35%
|
|
Gross Profit | 0.49 0.49 |
58%
58%
|
|
EBITDA | -54 -54 |
21%
21%
|
EBIT (Operating Income) EBIT | -56 -56 |
21%
21%
|
Net Profit | -58 -58 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nyxoah SA engages in the research and development, manufacture and sale of medical devices. It focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Its lead solution platform is based on the Genio system, a validated, user-centered, neurostimulation therapy for obstructive sleep apnea (OSA). The company was founded by Robert Taub and Adi Mashiach on July 15, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Head office | Belgium |
CEO | Olivier Taelman |
Employees | 146 |
Founded | 2009 |
Website | www.nyxoah.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.